EGFR and cancer: In the same manner, several studies have demonstrated that the dysregulation of CCND1 is associated with cancer progression while the over-expression of EGFR and EGFR-ligands as well as the dysregulation of the RAS/RAF/ERK signaling pathway are associated with the acquisition of drug resistance associated with cancer progression [84,85,86].